Abstract

The epithelial sodium channel (ENaC) participates in the regulation of plasma sodium and volume, and gain of function mutations in the human channel cause salt-sensitive hypertension. Roles for the arachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (EETs), in ENaC activity have been identified; however, their mechanisms of action remain unknown. In polarized M1 cells, 14,15-EET inhibited amiloride-sensitive apical to basolateral sodium transport as effectively as epidermal growth factor (EGF). The EET effects were associated with increased threonine phosphorylation of the ENaC β and γ subunits and abolished by inhibitors of (a) mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal regulated kinases 1 and 2 (MEK/ERK1/2) and (b) EGF receptor signaling. CYP2C44 epoxygenase knockdown blunted the sodium transport effects of EGF, and its 14,15-EET metabolite rescued the knockdown phenotype. The relevance of these findings is indicated by (a) the hypertension that results in mice administered cetuximab, an inhibitor of EGF receptor binding, and (b) immunological data showing an association between the pressure effects of cetuximab and reductions in ENaCγ phosphorylation. These studies (a) identify an ERK1/2-dependent mechanism for ENaC inhibition by 14,15-EET, (b) point to ENaC as a proximal target for EET-activated ERK1/2 mitogenic kinases, (c) characterize a mechanistic commonality between EGF and epoxygenase metabolites as ENaC inhibitors, and (d) suggest a CYP2C epoxygenase-mediated pathway for the regulation of distal sodium transport.

Highlights

  • The epoxygenase metabolites (EETs) inhibit ENaC by unknown mechanisms

  • M1 cells are derived from mouse collecting duct (CD) [26], express a functional ENaC [27, 28], and metabolize endogenous arachidonic acid to epoxyeicosatrienoic acids (EETs) as shown by the presence of 11,12, and 14,15-EET, and their corresponding dihydroxyeicosatrienoic acids in cell extracts

  • As with most cell preparations and organ tissues, greater than 90% of the EETs present in M1 cells are found as esters of cellular glycerophospholipids [25], and the cellular concentration of free, non-esterified EETs represent a fraction of the total

Read more

Summary

Background

The epoxygenase metabolites (EETs) inhibit ENaC by unknown mechanisms. Results: 14,15-EET stimulates an ERK1/2-catalyzed inhibitory phosphorylation of the ENaC ␤ and ␥ subunits. CYP2C44 epoxygenase knockdown blunted the sodium transport effects of EGF, and its 14,15-EET metabolite rescued the knockdown phenotype The relevance of these findings is indicated by (a) the hypertension that results in mice administered cetuximab, an inhibitor of EGF receptor binding, and (b) immunological data showing an association between the pressure effects of cetuximab and reductions in ENaC␥ phosphorylation. These studies (a) identify an ERK1/2dependent mechanism for ENaC inhibition by 14,15-EET, (b) point to ENaC as a proximal target for EET-activated ERK1/2 mitogenic kinases, (c) characterize a mechanistic commonality between EGF and epoxygenase metabolites as ENaC inhibitors, and (d) suggest a CYP2C epoxygenase-mediated pathway for the regulation of distal sodium transport. Inhibition of EGF receptor (EGFR) signaling abrogated the cellular effects of EGF and 14,15-EET on JNaϩ and caused hypertension in mice

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call